Don't miss the first issue of our new twice-monthly publication dedicated to cell and gene therapy. Cell and Gene Therapy Business Outlook offers the following:
Market Sizing and Forecasting of CAGT Markets
Executive News Summaries
Deals Between CAGT Companies Tracked
Financing
Trends in the Industry
Important Science That Will Shape Tomorrow’s Business
Company Profiling and Quarterly Results Summaries
Updates on Pipelines and Important Clinical Trials
Cell and Gene Therapy Tools
Cell and Gene Therapy CMOs
And More
Page Count: 51
Table of Contents
Untitled Chapter
Market Analysis
Focus on Cardiovascular and Blood Disorders
Overview of Cardiovascular and Blood Disorders
Market Outlook
Cardiovascular and Blood Disorder CGT Products
Introduction
Products on the Market
Products in Development
Market Opportunity
Market Size and Growth
Regional Market
Market Forecast Indicators
Executive News Brief
Cell and Gene Therapy Market Financing
Cell and Gene Therapy Firms Net Nearly $11 Billion in Financing So Far in 2021
Cell and Gene Therapy Market News and News Analysis
Nobel Prize Winner Doudna Shares Perspectives on Future of CRISPR Gene Editing
Danaher to Acquire Aldevron for $9.6 Billion
BioMarin’s PKU Gene Therapy Treats First Patient in U.S.
Bayer Moves Forward on Two Novel Therapeutics for Parkinson’s Disease
Optogenetic Gene Therapy Provides Hope for Retinitis Pigmentosa Patients
Lilly and MiNA Join Forces to Develop saRNA-based Therapeutics
Cell and Gene Therapy Market Corporate Profiles and Quarterly Results
Selected Company Profiles and Q1 Results
Orchard Therapeutics Advances Product Dev, Trims Loss
Product Development Update
Net Loss Declines in Q1 2021
Sanofi Forges Ahead with CGT Lineup, Grows on Constant Basis
Cell and Gene Therapy Products Currently in Phase I
SKU 21-015
In vitro diagnostic (IVD) test volumes are the gold standard for sizing the market opportunity for new entrants with diagnostic products, and they can be useful for existing product marketers. The market analysis in Kalorama’s IVD Test…